Cour Pharmaceuticals recognized as a top innovator in Fierce Biotech’s 2024 Fierce 15 8/28/2024 Category: FEATURED IN, PORTFOLIO NEWS
Angelini Ventures' parent company Angelini Industries reports significant growth in FY 2023 consolidated financial statements 7/19/2024 Category: FEATURED IN
Angelini Ventures invests into extended €75.8 million Series C financing round for Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized cancer vaccines 3/21/2024 Category: INVESTMENTS
Inside Angelini Ventures: CEO Paolo di Giorgio discusses innovative investment strategy in Innlifes interview 2/12/2024 Category: FEATURED IN
Avation Medical raises $22M+ to launch closed-loop wearable neuromodulation tech for overactive bladder treatment 2/5/2024 Category: INVESTMENTS
Episode 1 of Stories Behind the Change the first podcast by Angelini Industries spotlights our portfolio company Serenis 2/1/2024 Category: FEATURED IN
Angelini Ventures